Desferrithiocin is a more potent antineoplastic agent than desferrioxamine

British Journal of Pharmacology

Volumn 135, Issue 6, 2002, Pages 1393-1402

  Kicic, Anthony ^a   Chua, Anita C G ^a   Baker, Erica ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Desferrioxamine; Desferrithiocin; Fe chelators; Fe uptake; Hepatocellular carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; DEFEROXAMINE; DEFERRIFERRITHIOCIN; IRON; IRON CHELATING AGENT; MALTOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; IRON CHELATION; LIVER CELL; LIVER CELL CARCINOMA; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0036214907     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704507     Document Type: Article

References (58)

1. Controlled synthesis of HbsAg in a differentiated human liver carcinoma-derived cell line
2. Metal complex formation of a new siderophore desferrithiocin and of three related ligands
3. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-napththylaldehyde using the hepatocyte in culture
4. Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic
5. Desferrioxamine inhibition of human neuroblastoma viability and proliferation
6. A comparative evaluation of iron clearance models
7. A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model
8. An investigation of desferrithiocin metabolism
9. Synthesis and biological evaluation of napthyldesferrithiocin iron chelators
10. Evaluation of the desferrithiocin pharmacophore as a vector for hydroxamates
11. Effects of C-4 stereochemistry and C-4′ hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues
12. Desazadesmethyldesferrithocin analogues as orally effective iron chelators
13. The effect of desferrithiocin, an oral iron chelator, on T-cell function
14. Antineuroblastoma activity of desferrioxamine in human cell lines
15. Mechanisms of antinueoroblastoma activity of desferrioxamine in vitro
16. The effect of desferrioxamine on transferrin receptors, the cell cycle and growth rates of human leukaemic cells
17. 1 phase of the cell cycle
18. Antiproliferative effect of deferiprone on the HepG2 cell line
19. Effects of different transferrin forms on transferrin receptor expression, Iron uptake and cellular proliferation of human leukaemic HL60 cells
20. Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumour cell growth in culture and in vivo
21. The iron chelator LI potentiates oxidative DNA damage in iron overloaded liver cells
22. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effects of the ligands on molecular targets involved in proliferation
23. Effects of desferrioxamine on normal and leukaemic human haematopoietic cell growth: In vitro and in vivo studies
24. Effects of a single course of deferoxamine in neuroblastoma patients
25. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thioteps (D-CE-CaT): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma
26. D-CEaT: A breakthrough for patients with neuroblastoma
27. Deferoxamine (D) followed by cytoxan (C), etoposide (E), carboplatin (Ca), thio-TEPA (T), induction regimen in advanced neuroblastoma: Preliminary results
28. Relation of oxygenation and temperature in preservation of tissues by refrigeration
29. Effect of iron and desferrioxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines
30. The role of endocytosis in the transferrin uptake by reticulocytes and bone marrow cells
31. Iron chelators induce apoptosis in proliferating cells
32. Maltol (3-hydroxy-2-methyl-4-pyrone) toxicity in neuroblastoma cell lines and primary murine fetal hippocampal neuronal cultures
33. Prospects for oral iron chelation therapy
34. Effect of desferrioxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells
35. Effect of anticancer drugs and desferrioxamine in combination with radiation on hepatoma cell lines
36. The mechanism of antiproliferative effect of desferrioxamine on human hepatoma cell lines
37. Hepatocellular carcinoma
38. Deferoxamine: A reversible S-phase inhibitor of human lymphocyte proliferation
39. An animal model of iron overload and its application to study hepatic ferritin iron mobilization by chelators
40. Rapid colorimetric assay for cellular growth and survival: Application for proliferation and cytotoxicity assays
41. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium
42. Differential effects of liposomes-entrapped desferrioxamine on proliferation and erythroid differentiation of murine Erythroleukemia Friend cells
43. Cell cycle specific effects of deferoxamine on human and murine haematopoietic progenitor cells
44. Industrial aspects of iron chelators: Pharmaceutical applications
45. Cell cycle-dependent inhibition of the proliferation of human neural tumour cell lines by iron chelators
46. The effects of the iron (III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell
47. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents
48. The potential of iron chelators of the pyridoxal isonicotonoyl hydrazone class as effective iron chelators II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-napththylaldehyde benzoyl hydrazone
49. Epidemiology of hepatocellular carcinoma
50. Hepatocellular carcinoma
51. Ferritin production and desferrioxamine cytotoxicity in human neuroblastoma cell lines
52. Iron chelators in vitro inhibitory effect on the liver stage of rodent and human malaria
53. Effect of desferrioxamine and hydroxypyridones on haemopoietic progenitors and neuroectodermal tumour cells
54. Tumour cell cytotoxicity of a novel metal chelator
55. The in vitro response of human tumour cells to desferrioxamine is growth medium dependent
56. Enzymology of cancer cells
57. Regulation of ribonucleotide reductase activity and its possible exploitation in chemotherapy
58. A non human primate model for the study of oral iron chelators